Understanding and treating prolonged recovery from NMDA receptor encephalitis
Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage
This study is trying to understand how people recover from anti-NMDA receptor encephalitis and see if new tools and treatments can help improve their brain function and behavior.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica Academic / other |
| Locations | 1 site (Barcelona, Catalonia) |
| Trial ID | NCT06183788 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients recovering from anti-NMDA receptor encephalitis, a condition that causes severe neurological and psychiatric issues. It aims to characterize the post-acute stage of the disease, develop remote tools for monitoring cognitive and behavioral deficits, and assess the impact of cognitive rehabilitation. Additionally, the study will identify biomarkers associated with both acute and post-acute stages and utilize a mouse model to explore underlying mechanisms and potential treatments.
Who should consider this trial
Good fit: Ideal candidates are patients aged 12 years and older who are in the post-acute stage of NMDA receptor encephalitis and have been discharged from the hospital within the last six months.
Not a fit: Patients who are unable to provide informed consent or cannot travel to the study center may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better recovery outcomes for patients suffering from NMDA receptor encephalitis.
How similar studies have performed: While this approach is novel in its specific focus on the prolonged recovery stage of NMDA receptor encephalitis, similar studies have shown promise in understanding and treating other autoimmune encephalitides.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥12 years old with NMDARe in the post-acute stage of the disease; * ≤6 months from hospital discharge (acute phase) Exclusion Criteria (one of the following): * Inability to obtain informed consent; * inability to travel to the center.
Where this trial is running
Barcelona, Catalonia
- Hospital Clínic de Barcelona — Barcelona, Catalonia, Spain (Recruiting)
Study contacts
- Principal investigator: Josep Dalmau, MD, PhD — Hospital Clínic
- Study coordinator: Josep Dalmau, MD,PhD
- Email: jdalmau@clinic.cat
- Phone: 34 93 227 1738
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.